Alembic Pharma Q3 FY26: Revenue up 11%, PAT at Rs 133 cr
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharma posted Q3 FY26 consolidated revenue of Rs 1,876 cr, up 10.8% YoY. 9M revenue grew 12% to Rs 5,497 cr. Q3 PAT was Rs 133 cr, down 4% YoY, but 9M PAT rose 11% to Rs 472 cr. An exceptional charge of Rs 42 cr from new Labour Codes hit Q3 profits. Auditor is now KKC and Associates (previously KC Mehta). Board appointed Rajkumar Baheti as Non-Executive Director from April 2026.
Q3 PAT dipped on one-time Labour Code charge; underlying business grew in double digits. New board role and auditor change noted.